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Efeito da suplementação com ácido linoléico
conjugado sobre a atividade da lípase lipoprotéica
em cultura de adipócitos 3T3-L1
Adriana Prais BOTELHO2
Lilia Ferreira SANTOS-ZAGO2,3
Admar Costa de OLIVEIRA4 (in memorian)
A B S T R A C T
Supplementation with conjugated linoleic acid may reduce fat body mass and increase lean body mass in
various species. Some studies have demonstrated that conjugated linoleic acid reduces body fat, in part,
by inhibiting the activity of lipoprotein lipase in adipocytes. The objective of this work was to study the
effect of conjugated linoleic acid supplementation on lipoprotein lipase activity in 3T3-L1 adipocyte
culture. 3T3-L1 adipocytes received linoleic acid (group C) or conjugated linoleic acid (group AE,
supplemented with AdvantEdge® CLA, and group CO, supplemented with CLA One®) in concentrations of
1 mmol/L. Heparin-releasable lipoprotein lipase activity was analyzed by means of a 3T3-L1 adipocyte culture.
After 7 days, heparin-releasable lipoprotein lipase activity was lower in the groups AE and CO supplemented
with conjugated linoleic acid. These results suggest that one of the mechanisms by which CLA is capable of
reducing body fat is by reducing lipoprotein lipase activity.
Indexing terms: Linoleic acid, conjugated. Lipoprotein lipase. Nutrition. Dietary supplements.
1 Nota Científica elaborada a partir do Projeto de Pesquisa intitulado “A suplementação com ácido linoléico conjugado e o
perfil lipídico, composição corporal e peroxidação lipídica em ratos”. Apoio: Fundação de Amparo à Pesquisa do Estado de
São Paulo (Processo nº 2003/07648-4) e desenvolvido no Departamento de Alimentos e Nutrição, Faculdade de Engenharia
de Alimentos, Universidade Estadual de Campinas.
2 Universidade Estadual de Campinas, Faculdade de Engenharia de Alimentos, Programa de Doutorado em Alimentos e
Nutrição, Departamento de Alimentos e Nutrição. R. Monteiro Lobato, 80, Cidade Universitária Zeferino Vaz, 13083-862,
Campinas, SP, Brasil. Correspondência para/Correspondence to: A.P. BOTELHO. E-mail: <abotelho@fea.unicamp.br>.
3 Pontifícia Universidade Católica de Campinas, Centro de Ciências da Vida, Faculdade de Nutrição. Campinas, SP, Brasil.
4 Universidade Estadual de Campinas, Faculdade de Engenharia de Alimentos, Departamento de Alimentos e Nutrição.
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R E S U M O
A suplementação com ácido linoléico conjugado pode reduzir a gordura corporal e aumentar a massa magra
em diferentes espécies. Alguns estudos têm demonstrado que o ácido linoléico conjugado reduz a gordura
corporal, por meio da inibição da atividade de lípase lipoprotéica em adipócitos. O objetivo deste estudo foi
avaliar o efeito da suplementação com uma mistura de isômeros do ácido linoléico conjugado sobre a
atividade da lípase lipoprotéica em cultura de adipócitos 3T3-L1. Os adipócitos 3T3-L1 receberam ácido
linoléico (grupo controle) ou ácido linoléico conjugado (grupo AE, suplementado com AdvantEdge® CLA, e
grupo CO, suplementado com CLA One®) na concentração de 1 mmol/L. A atividade de lípase lipoprotéica livre
de heparina foi analisada pela média da cultura de adipócitos. Após 7 dias, a atividade da lípase lipoprotéica
livre de heparina mostrou menores valores nos grupos AE e CO, suplementados com ácido linoléico conjugado.
Estes resultados sugerem que um dos mecanismos pelo qual o ácido linoléico conjugado seja capaz de reduzir
a gordura corporal é a partir da redução da atividade da lípase lipoprotéica.
Termos de indexação: Ácido linoléico conjugado. Lípase lipoprotéica. Nutrição. Suplementos dietéticos.
Conjugated Linoleic Acids (CLA),
substances that occur naturally in meats and dairy
products, are a group of geometrical and positional
isomers of linoleic acid with conjugated double
bonds1,2. CLA is produced in the rumen by the
incomplete biohydrogenation of dietary
polyunsaturated fatty acids, and also by the
desaturation of C18:1 trans-11 fatty acid by the
enzyme delta-9-desaturase present in mammary
glands and adipose tissue3. Numerous studies
associate CLA consumption with beneficial health
effects in humans, among them anticarcinogenesis,
reduction of atherosclerosis, modulation of the
immune system, and enhancement of bone
mineralization4,5. One of the most interesting
aspects of CLA is its ability to reduce body fat
while increasing lean body mass. The mechanisms
proposed to explain these changes are still
controversial. CLA ingestion has been associated
with decreased preadipocyte proliferation and
differentiation, reduced esterification of fatty acids
into triacylglycerols, increased energy expenditure,
and changes in the activity of the enzymes
carnitine palmitoyltransferase, lipoprotein lipase,
and the hormone leptin, among others6,7. Some
studies have demonstrated that CLA reduces body
fat, in part, by inhibiting the activity of Heparin-
Releasable Lipoprotein Lipase (HR-LPL) in
adipocytes8,9. The objective of this work was to
assess the effect of conjugated linoleic acid
supplementation on the activity of the Lipoprotein
Lipase (LPL) enzyme in a 3T3-L1 adipocyte culture.
3T3-L1 adipocytes were purchased from
Cell Bank (Rio de Janeiro, RJ, BR). Dulbecco´s
modified Eagle´s medium was obtained from Gibco
BRL (Paisley, UK). Both fetal bovine serum and
human serum were obtained from Bio Whittaker
(Verviers, Belgium). 12-Well cell-culture plates
were obtained from Costar (NY, USA).
Methylisobutylxanthine, insulin, bovine serum
albumin (BSA, essential fatty acid-free),
dexamethasone, heparin (10.000U/mg), 3H-triolein,
Picofluor scintillation solution, 60% linoleic acid
supplement and all other chemicals were obtained
from Sigma-Aldrich (St. Louis, USA). The
conjugated linoleic acid supplements used in the
study were AdvantEdge® CLA 75% obtained from
EASTM (Golden, CO, USA) and CLA One® Free
Fatty Acid Oil 75% obtained from Pharmanutrients
(Gurnee, IL, USA). CyQuant® Cell Proliferation
Assay Kit (C7026) was obtained from Molecular
Probes (Oregon, USA). The fatty acid profiles were
determined by methylation, according to the
Christie method10.
Total CLA contents, their isomeric distribution,
and fatty acid profiles of linoleic acid and
conjugated linoleic acid mixtures were analyzed
by gas chromatography with a capillary silica
column CP SIL 88 (0.25mm x 0.2µm x 100m), as
described by Sehat et al.11. Determination of
lipoprotein lipase activity was done in a 3T3-L1
adipocyte culture12. The 3T3-L1 adipocytes were
cultured in a basic medium composed of Dulbecco’s
modified Eagle’s medium, with 10% added fetal
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bovine serum. Temperature was kept constant at
37°C; the atmosphere was humidified, and
contained 10% CO2. After 2 days, cell differentiation
was induced by adding 0.5mmol/L of methyliso-
butylxanthine, 0.25µmol/L of dexamethasone and
1µg/L of insulin to the basic medium. After 2 days
the medium was replaced by another one
containing only 10% of fetal bovine serum and
insulin (1µg/L). Before starting the assay with the
experimental medium, cell viability was evaluated
with the CyQuant® Cell Proliferation Assay Kit. The
experimental medium was prepared using the
basic medium and adding bovine serum albumin
(BSA), to a final concentration of 0.25mmol/L. The
pH of this basic medium-BSA complex was
adjusted to 10.0 with a 1mol/L NaOH solution. In
the next stage, linoleic acid supplement was added
to group C, and commercial conjugated linoleic
acid mixtures AdvantEdge® (EASTM) and CLA One®
(Pharmanutrients) to groups AE and CO, respectively,
until a solution of 1mmol/L of fatty acid
concentration was reached. At this point, the pH
was adjusted to 7.4 with a 1mol/L HCl solution.
The solution containing the basic medium, BSA
and fatty acids was sonicated in ultrasound for 1
hour, and diluted with the basic medium-BSA
complex to a final fatty acid concentration of
100µmol/L. After 7 days incubating the mature
adipocytes in the experimental medium, the latter
was discarded, and the cells were rinsed with a
0.5mL phosphate buffer (PBS) (pH 7.4), and
cultured for 1 hour in a heparin solution and
phosphate buffer (0.3mL per well at 10U/L of
heparin).
The culture dishes were then placed in an
ice bath, and the heparin-PBS solution was
collected from each well for determination of
heparin-releasable lipoprotein lipase activity. For
this determination, a stock solution was prepared
with 3H-triolein (45µCi, 600mg of triolein),
phosphatidylcholine (36mg) and glycerol (10mL).
The following were added to this stock solution:
Tris-HCl buffer (pH 8.2 at 37°C), 3% BSA solution
in 0.78M NaCl, and inactivated human serum, in
the proportion of 1:4:1:1 (v/v/v/v). For the
measurement of lipoprotein lipase activity, 100µL
of this solution were added to 100µL of the
heparin-PBS solution followed by incubation in a
water bath at 37°C for 1 hour. The reaction was
interrupted by adding to the mixture 3mL of
methanol, dichloromethane and heptane in the
proportion of 1.41:1.25:1 (v/v/v). After that, 1mL
of the supernatant aqueous phase was collected
and transferred to a vial containing 10mL of
scintillation liquid (Picofluor). Sample radioactivity
was counted in a liquid scintillation counter
(Beckman LS 6000TA), and the heparin-releasable
lipoprotein lipase (HR-LPL) activity (EC 3.1.1.34,
10U heparin/mL media for 1 hour at 37ºC) was
measured as described by Nilson-Ehle et Schotz13.
Protein was determined as described by Lowry
et al14.
Results are expressed as Means (M)
Standard Error (SE). Data were analyzed statistically
by ANOVA using the Statistical Analysis System
(SAS)15. The Tukey test was used to test the
differences among groups. Differences were
considered significant if p≤0.01.
The predominant composition of the
isomers in the 60% linoleic acid supplement
acquired from Sigma and the commercial
conjugated linoleic acid mixtures 75%
AdvantEdge®, CLA (EASTM), and 75% CLA One®
Free Fatty Acid Oil 1CLA1-FFBL-KG (Pharmanutrients),
expressed in g/100g of fatty acids, can be seen in
Table 1. Supplements used in this research
contained 79.27 and 73.08% of CLA for the brands
AdvantEdge® CLA e CLA One®, respectively, and
the proportion between the predominant isomers
cis-9, trans-11 and trans-10, cis-12 was
approximately 1:1 (Table 1).
LPL activity was analyzed by means of a
3T3-L1 adipocyte culture. After 7 days, the HR-LPL
activity of groups AE and CO supplemented with
CLA was significantly lower (p≤0.01) (Figure 1).
Similar results were obtained when 3T3-L1
adipocyte cultures were treated with an increasing
amount (20 to 200µmol/L) of a CLA isomer
mixture. CLA treatment significantly reduced
heparin-releasable lipoprotein lipase activity and
intracellular concentrations of triacylglycerol and
glycerol8. In order to investigate which isomer
would be responsible for this alteration, 3T3-L1
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adipocyte cultures were treated with trans-10, cis-
12 and cis-9, trans-11 CLA isomers separately.  The
trans-10, cis-12 isomer reduced lipoprotein lipase
activity, intracellular triacylglycerol and glycerol,
and enhanced glycerol release into the medium.
By contrast, the cis-9 trans-11 CLA isomer did not
affect these biochemical activities9. More recently,
CLA significantly reduced LPL activity in 3T3-L1
adipocytes, confirming those results16. In order to
discover the key structural feature of trans-10
cis-12 CLA responsible for inhibiting HR-LPL, Park
et al.17 tested fatty acids that are structurally related
to trans-10, cis-12 CLA using 3T3-L1 adipocytes.
The results demonstrated that trans-10, cis-12 CLA
is directly responsible for reducing HR-LPL
activity, and that the trans-10 double bond may
be the key17.
This experiment, which used a 3T3-L1
adipocyte culture, indicated that CLA reduced LPL
activity. Assuming that in vitro experiments reflect
physiological changes that occur in vivo, these
data can suggest that the CLA is capable of
reducing body fat in different experimental
models8,9. In order to assess the potential
involvement of altered lipoprotein lipase activity
in the reduction of body fat, Zabala et al.18
investigated the effects of trans-10, cis-12 CLA in
hamster adipose tissue. After the experimental
period (6 weeks), the group receiving trans-10,
cis-12 showed a significant reduction in lipoprotein
lipase activity compared with the control group
given linoleic acid. The authors concluded that
the activity of LPL can be regulated at many levels,
including transcription, translation, processing and
transport from adipocytes to endothelial cells. Both
total and HR-LPL activities were reduced in the
CLA-fed groups, indicating that the reduction in
mRNA levels leads one to the conclusion that the
regulation of LPL by CLA takes place at the
transcriptional level. Peroxisome proliferator-
activated receptor γ (PPARγ) is a transcriptional
factor, highly expressed in adipose tissue, which
plays an important role in the regulation of lipid
metabolism. Its activation promotes lipid storage
by stimulation of LPL. Zabala et al18 found that
the expression of this nuclear receptor was
significantly reduced by feeding CLA feeding.
Similar results were obtained when human primary
adipocyte cultures were treated with trans-10,
cis-12 CLA isomer19.
In conclusion, the results obtained in this
study confirm the ability of CLA to reduce LPL
activity, indicating that the inhibition of LPL activity
seems to be a mechanism underlying body fat
reduction. Further research using different
experimental conditions is needed to characterize
the effects of CLA on lipogenesis, and the role of
these effects in the ability of CLA to reduce body
fat.
Table 1.  Fatty acid composition of linoleic acid and commercial conjugated linoleic acid mixtures.
C18:2 cis-9, cis-12
C18:2 cis-9, trans-11 CLA
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CLA One® Free Fatty Acid
Oil 75% 1CLA1-FFBL-kg
Figure 1. Effects of CLA on heparin-releasable lipoprotein lipase
activity in 3T3-L1 adipocytes. Values represent mean ±
SE. (n=12, taken from three independent experiments).
Note: *Asterisks indicate statistical difference according to the Tukey
test (p≤0.01).
C: control group; AE: group supplemented with AdvantEdge®
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